-
Research Progress of FAK inhibitor
Yi/PharmaSources
July 10, 2023
Recently, Amplia Therapeutics Limited announced its FAK inhibitor AMP945 under research combined with FOLFIRINOX was effective on the preclinical model of pancreatic cancer.
-
R&D Progress of Ubiquitin-proteasome Pathway and Its Drug
Xiao Nisha/PharmaSources
July 10, 2023
As a great protein machine, ubiquitin-proteasome has become an important target for scientists to develop potentially effective drugs for diseases in recent decades of research.
-
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines
Daivd Orchard Webb/PharmaSources
July 03, 2023
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
-
The Dynamic Diabetes and Metabolic Disorder Treatment Landscape
Daivd Orchard Webb/PharmaSources
July 03, 2023
Diabetes is a chronic medical condition characterized by high levels of glucose in the blood.
-
Zai Lab: How To Go Further after Cancelling B?
Zhaoxiaoxia/PharmaSources
July 03, 2023
On November 11, 2022, Zai Lab announced that its HKEX stock code suffix -B is cancelled officially, which is another "Cancel B" company in Hong Kong stock market 18A after Baekje, Innovent, TopAlliance, Henlius and CanSino Biologics.
-
The New Indication of Venetoclax, a Popular Drug of AbbVie, Declared in China
Dupeipei/PharmaSources
July 03, 2023
On June 21, Class 5.1 import application for 「Venetoclax tablet」 submitted by AbbVie was accepted by the CDE.
-
Overview of New "Don't Eat Me" Target CD24 Research
Zhaoruijie/PharmaSources
July 03, 2023
Recently, Antengene Corporation announced that the Phase I clinical trial application (IND) of its global first anti-CD24 monoclonal antibody, ATG-031, had been approved by FDA.
-
Key progress has been achieved in many clinical trials of Abexinostat.
Jianghuzhiyuan/PharmaSources
June 27, 2023
How much progress has been made in the research and development of HDAC inhibitor?
-
Research progress of dual-target CAR-T in China from the perspective of the ASCO 2023
Xiaobin/PharmaSources
June 27, 2023
At the ASCO this year, Gracell Bio announced the long-term follow-up data of its multi-center clinical study of CAR-T therapy with GC012F for recurrent/refractory multiple myeloma (R/R MM) in the form of oral report at the annual meeting.
-
Chinese Pharmaceutical Market Overview by ChatGPT
ChatGPT/PharmaSources
June 25, 2023
Top phamaceutical suppliers and ingredients are at PharmaSources.com.